AztraZeneca and Oxford University Vaccine: Interim Recommendations and more information

az vaccine

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 8 February 2021 for the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. 

Additional Information: